Switzerland
Gilead Sciences Switzerland Sàrl
General-Guisan-Strasse 8
6300 Zug
Switzerland
Phone: 41 (0)41 580 02 00 41 (0)41 580 02 00
Fax: 41 (0)41 580 02 98
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.
Gilead’s office in Zug is responsible for medical, sales and marketing activities for our products in Switzerland.
Relationships with Patient Organizations and NGOs
Gilead provided support to the following patient organizations and NGOs in 2019. The information is correct at the time of writing (April 2020). The information is subject to change and periodic updates. For a listing of previous years’ payments, click here.
Patient Organisation and NGO | Description of Activity | Amount Funded |
---|---|---|
AIDS HILFE BERN | Peer 2 Peer Projekt 2019 - 2021 | CHF 15,000 |
AIDS HILFE BERN | Movie "Positiv älter werden" 2018-2019 | CHF 10,000 |
AIDS-HILFE SCHWEIZ | Swiss Aids Federation International prides 2019 - Grant | CHF 25,000 |
LIFE4ME.PLUS TO FIGHT AIDS, HEPATITIS C AND TUBERCULOSIS | NOSTIGMA - Grant | CHF 10,750 |
LIFE4ME.PLUS TO FIGHT AIDS, HEPATITIS C AND TUBERCULOSIS | German Speaking HIV - News services - Grant | CHF 10,000 |
PATIENTUBE AG | Patient Videos "Hepatitis C - the value of a treatment" | CHF 6,250 |
PATIENTUBE AG | Presentation: 5yr SOF based-therapy | CHF 390 |
POSITIVRAT SCHWEIZ | Social media and external communications support - Grant | CHF 30,000 |
SHCA - SWISS HEPATITIS C ASSOCIATION | SLTC Attendance support | CHF 465 |
UNALONE | Re - launch of the website landing page and website users registration - Grant | CHF 10,000 |
VEREIN ZURICH PRIDE FESTIVAL | Strong in diversity | CHF 20,000 |
POSITIVE FRAUEN SCHWEIZ | Trainings on HIV treatments and HIV development | CHF 3,000 |
FACHSTELLE FÜR SEXUELLE GESUNDHEIT ZÜRICH SEGZ | Projekt 'Sexuelle Gesundheit bei du-bist-du' | CHF 2,000 |
Publication of Clinical Study Results
As of 2020, Gilead discloses clinical study results of newly authorized products in Switzerland by Swissmedic according to the requirements laid out in Art. 71-73 TPO (Ordinance on Therapeutic Products).
Products are listed in alphabetical order.
Product |
Active Substance |
Authorization Number |
Date of Authorization |
---|---|---|---|
Remdesivir |
68026 / 68043 |
25 Nov 2020 |
This page is intended for visitors outside of the United States.